Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study
05 12월 2023 - 3:54PM
Dow Jones News
By Mauro Orru
Roche Holding said its investigational treatment, inavolisib,
showed promise in a late-stage study to treat patients with breast
cancer.
The Swiss pharmaceutical company said Tuesday that the phase 3
study met its primary endpoint of progression-free survival,
showing that inavolisib, in combination with palbociclib and
fulvestrant, delivered a statistically significant and clinically
meaningful improvement compared to palbociclib and fulvestrant
alone.
While Roche acknowledged that overall survival data were
immature at this stage, it said it had observed a clear positive
trend. The inavolisib combination was well tolerated.
The group said inavolisib is an investigational, oral targeted
treatment with potential to provide durable disease control.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
December 05, 2023 01:39 ET (06:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Roche (QX) (USOTC:RHHBY)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Roche Holdings Ltd AG (QX) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Roche Holdings Ltd AG (QX) News Articles